SCHEMBL4776397

SCHEMBL4776397

Cc1cccc(CN2CCN(C(c3ccc(Cl)cc3Cl)C(N)C=O)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.52
HRH1 P35367 2/20 0.52
USP2 O75604 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52
HPN P05981 1/20 0.52
CHRM2 P08172 1/20 0.52
ADRA2A P08913 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
CHRM1 P11229 1/20 0.52
DRD2 P14416 1/20 0.52
ADRA2C P18825 1/20 0.52
CNR1 P21554 1/20 0.52
DRD1 P21728 1/20 0.52
DRD4 P21917 1/20 0.52
SLC6A2 P23975 1/20 0.52
HRH2 P25021 1/20 0.52
HTR2A P28223 1/20 0.52
SLC6A4 P31645 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4778352 0.90 ALDH1A1 (0.40) CYP3A4HRH1USP2CYP1A2CYP2D6
SCHEMBL4778576 0.84 FAAH (0.47) KCNH2ALDH1A1KDM4ELMNA
SCHEMBL4775561 0.83 MAPT (0.43) KCNH2MEN1KMT2AGAAMAPT
SCHEMBL4778381 0.78 LSS (0.40) CYP3A4MEN1KMT2ASIGMAR1
SCHEMBL4773088 0.77 SIGMAR1 (0.36) CNR1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4771297 0.75 NPSR1 (0.46) USP2CYP2C19ALDH1A1KDM4EMEN1
SCHEMBL4776514 0.74 SIGMAR1 (0.36) CYP3A4ALDH1A1KDM4ESIGMAR1
SCHEMBL21299953 0.72 CYP3A4 (0.51) CYP3A4HRH1USP2CYP1A2CYP2D6
SCHEMBL20415963 0.72 ALDH1A1 (0.83) CYP3A4HRH1USP2CYP1A2CYP2D6
SCHEMBL4774991 0.72 LMNA (0.39) CYP3A4CYP1A2CYP2D6CYP2C19HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed